Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Дилтиазем при фибрилляции предсердий: эффективность, безопасность, лекарствосберегающие свойства
________________________________________________
Beldiev S.N. Diltiazem in atrial fibrillation: effectiveness, safety, drug-sparing properties. Consilium Medicum. 2015; 17 (10): 45–49. DOI: 10.26442/2075-1753_2015.10.45-48
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ключевые слова: фибрилляция предсердий, дилтиазем, b-адреноблокаторы, дигоксин, апиксабан.
________________________________________________
Key words: atrial fibrillation, diltiazem, b-blockers, digoxin, apixaban.
2. Vaughan-Sarrazin MS, Mazur A, Chrischilles E, Cram P. Trends in the pharmacologic management of atrial fibrillation: Data from the Veterans Affairs health system. Am Heart J 2014; 168 (1): 53–9.e1.
3. Lip GY, Laroche C, Dan GA et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2014; 16: 308–19.
4. Kotecha D, Holmes J, Krum H et al. on behalf of the Beta-Blockers in Heart Failure Collaborative Group. Efficacy of b blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014; 384: 2235–43.
5. Farshi R, Kistner D, Sarma JS et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol 1999; 33: 304–10.
6. Rathore SS, Curtis JP, Wang Y et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289: 871–8.
7. Khan SS, Gheorghiade M. Digoxin use in atrial fibrillation: a critical reappraisal. Lancet 2015; 385: 2330–2.
8. Bauman JL, DiDomenico RJ, Viana M, Fitch M. A method of determining the dose of digoxin for heart failure in the modern era. Arch Intern Med 2006; 166: 2539–45.
9. Bangalore S, Makani H, Radford M et al. Clinical outcomes with b-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med 2014; 127: 939–53.
10. Messerli FH, Hansen JF, Gibson RS et al. Heart rate-lowering calcium antagonists in hypertensive post-myocardial infarction patients. J Hypertens 2001; 19: 977–82.
11. Hansson L, Hedner T, Lund-Johansen P et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359–65.
12. Skanes AC, Healey JS, Cairns JA et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012; 28: 125–36.
13. Ulimoen SR, Enger S, Carlson J et al. Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation. Am J Cardiol 2013; 111: 225–30.
14. Ulimoen SR, Enger S, Pripp AH et al. Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation. Eur Heart J 2014; 35: 517–24.
15. National Clinical Guideline Centre (UK). Atrial fibrillation: The management of atrial fibrillation. London: National Institute for Health and Care Excellence (UK), 2014. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0068959/pdf/TOC.pdf
16. Frost CE, Byon W, Song Y et al. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol 2015; 79: 838–46.
17. Food and Drug Administration. ELIQUIS (apixaban) tablets for oral use. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202155s006lbl.pdf
18. Food and Drug Administration: Center for drug evaluation and research. Apixaban (Eliquis): clinical pharmacology and biopharmaceutical review. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000ClinPharmR.pdf
19. ФАРМ-индекс – российский фармпортал, цены в аптеках, наличие лекарств на рынке. http://www.pharmindex.ru / FARM-indeks – rossiiskii farmportal, tseny v aptekakh, nalichie lekarstv na rynke. http://www.pharmindex.ru [in Russian]
20. Martin JE, Daoud AJ, Schroeder TJ, First MR. The clinical and economic potential of cyclosporin drug interactions. Pharmacoeconomics 1999; 15: 317–37.
________________________________________________
1. Natsional'nye rekomendatsii po diagnostike i lecheniiu fibrilliatsii predserdii. 2012. http://www.scardio.ru/content/Guidelines/FP_rkj_13.pdf [in Russian]
2. Vaughan-Sarrazin MS, Mazur A, Chrischilles E, Cram P. Trends in the pharmacologic management of atrial fibrillation: Data from the Veterans Affairs health system. Am Heart J 2014; 168 (1): 53–9.e1.
3. Lip GY, Laroche C, Dan GA et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2014; 16: 308–19.
4. Kotecha D, Holmes J, Krum H et al. on behalf of the Beta-Blockers in Heart Failure Collaborative Group. Efficacy of b blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014; 384: 2235–43.
5. Farshi R, Kistner D, Sarma JS et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol 1999; 33: 304–10.
6. Rathore SS, Curtis JP, Wang Y et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289: 871–8.
7. Khan SS, Gheorghiade M. Digoxin use in atrial fibrillation: a critical reappraisal. Lancet 2015; 385: 2330–2.
8. Bauman JL, DiDomenico RJ, Viana M, Fitch M. A method of determining the dose of digoxin for heart failure in the modern era. Arch Intern Med 2006; 166: 2539–45.
9. Bangalore S, Makani H, Radford M et al. Clinical outcomes with b-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med 2014; 127: 939–53.
10. Messerli FH, Hansen JF, Gibson RS et al. Heart rate-lowering calcium antagonists in hypertensive post-myocardial infarction patients. J Hypertens 2001; 19: 977–82.
11. Hansson L, Hedner T, Lund-Johansen P et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359–65.
12. Skanes AC, Healey JS, Cairns JA et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012; 28: 125–36.
13. Ulimoen SR, Enger S, Carlson J et al. Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation. Am J Cardiol 2013; 111: 225–30.
14. Ulimoen SR, Enger S, Pripp AH et al. Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation. Eur Heart J 2014; 35: 517–24.
15. National Clinical Guideline Centre (UK). Atrial fibrillation: The management of atrial fibrillation. London: National Institute for Health and Care Excellence (UK), 2014. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0068959/pdf/TOC.pdf
16. Frost CE, Byon W, Song Y et al. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol 2015; 79: 838–46.
17. Food and Drug Administration. ELIQUIS (apixaban) tablets for oral use. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202155s006lbl.pdf
18. Food and Drug Administration: Center for drug evaluation and research. Apixaban (Eliquis): clinical pharmacology and biopharmaceutical review. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000ClinPharmR.pdf
19. FARM-indeks – rossiiskii farmportal, tseny v aptekakh, nalichie lekarstv na rynke. http://www.pharmindex.ru [in Russian]
20. Martin JE, Daoud AJ, Schroeder TJ, First MR. The clinical and economic potential of cyclosporin drug interactions. Pharmacoeconomics 1999; 15: 317–37.
ГБОУ ВПО Тверской государственный медицинский университет Минздрава России. 170100, Россия, Тверь, ул. Советская, д. 4
beldiev@yandex.ru
________________________________________________
Tver State Medical University of the Ministry of Health of the Russian Federation. 170100, Russian Federation, Tver, ul. Sovetskaja, d. 4
sbeldiev@yandex.ru